AzTrials
AzTrials

HIVPhase 1NCT00736905

TMC278-TiDP6-C130: Pharmacokinetics, Safety and Tolerability of TMC278 in Subjects With Mildly or Moderately Impaired Hepatic Function.

A Phase 1 study testing TMC278 in people with HIV and AIDS, run by Tibotec Pharmaceuticals, Ireland.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The purpose of this study is to investigate the pharmacokinetics (how the drug is absorbed into the bloodstream, distributed in the body and eliminated from the body) after a single dose and after repeated administration of TMC278 administered once daily for 11 days in subjects with mild or moderate hepatic impairment… Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
HIV, AIDS, Hepatic Impairment
What is being tested?
TMC278
How many people
32 participants
Where
No sites listed yet
Study dates
Jun 2008to Nov 2009
Phase
Phase 1

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Non smoking or smoking no more than 10 cigarettes, or 2 cigars, or 2 pipes per day for at least 3 months prior to selection
  • Body Mass Index (BMI, weight in kg divided by the square of height in meters) of 18.0 to 32.0 kg/m2, extremes included
  • Only for subjects with hepatic impairment: History of hepatic disease
  • Documented liver cirrhosis
  • Mild or moderate liver function impairment
  • Only for healthy control subjects: Healthy on the basis of a physical examination, medical history, electrocardiogram (ECG), vital signs and the results of blood biochemistry and hematology tests and a urinalysis
  • Matched to a subject with hepatic impairment with regards to sex, age (± 5 yrs), and BMI (± 15%).

Who cannot join

  • No positive HIV test
  • No females, except if postmenopausal since more than 2 years, or posthysterectomy, or post tubal ligation
  • No barbiturate, amphetamine, recreational or narcotic drug use
  • No use of more than 1 unit of alcoholic beverages per day
  • No positive urine drug test
  • No active gastrointestinal disease (with the exception of liver cirrhosis in the hepatically impaired subjects), cardiovascular, neurologic, psychiatric, metabolic, renal, respiratory, inflammatory, or infectious disease
Show all 25Show fewer
  • No currently significant diarrhea, gastric stasis, or constipation
  • No history of any significant skin disease
  • No previously demonstrated clinically significant allergy or hypersensitivity to any of the excipients of the investigational medication administered in this trial (i.e. TMC278)
  • Not previously participated in more than 1 trial with TMC125, TMC120 and/or TMC278 or having developed a rash, erythema or urticaria while participating in a trial with the aforementioned compounds
  • No participation in an investigational drug trial within 60 days prior to the first administration of trial medication
  • No donation of blood or plasma or significant blood loss within the 60 days preceding the first administration of trial medication
  • No vulnerable subjects
  • No subjects who are not able to read or write
  • Only for subjects with hepatic impairment: No acute or active hepatitis
  • No evidence of hepatic decompensation
  • No grade 3 or 4 encephalopathy
  • No hepatic carcinoma
  • No hepatorenal syndrome
  • No severe liver insufficiency
  • Not an active candidate for liver transplantation
  • No grade 3 laboratory abnormalities present with the exception of laboratory abnormalities related to hepatic impairment
  • Only for healthy control subjects: No hepatitis A, B or C infection
  • No current hepatic disease
  • No subjects with certain lab abnormalities.

About this study

Official title: Pharmacokinetics, Safety and Tolerability of TMC278 in Subjects With Mildly or Moderately Impaired Hepatic Function

The purpose of this study is to investigate the pharmacokinetics (how the drug is absorbed into the bloodstream, distributed in the body and eliminated from the body) after a single dose and after repeated administration of TMC278 administered once daily for 11 days in subjects with mild or moderate hepatic impairment (impaired liver function), compared with healthy control subjects. Furthermore the short-term safety and tolerability (how well the body tolerates the drug) of TMC278 will be assessed.

Read the detailed description

Human immunodeficiency virus (HIV)-infected patients are routinely being treated with combinations of 3 or 4 drugs (highly active antiretroviral therapy [HAART]), to reduce the risk of viral resistance development. Development of new potent antiretroviral (ARV) drugs is urgently needed to prolong suppression of viral replication in subjects infected with HIV. This is a Phase I, open-label, parallel, controlled, sequential study to investigate the single-dose and steady-state pharmacokinetics, and short-term safety and tolerability of TMC278 in subjects with mild or moderate hepatic impairment compared to subjects with normal hepatic function. The trial aims to provide guidance on administration and dose recommendations of TMC278 in subjects with mildly or moderately impaired hepatic function. The study population will consist of a total of 32 male and female subjects between 18 and 65 years. Panel A will consist of 8 subjects with mild hepatic impairment and 8 healthy subjects matched for sex, age (± 5 yrs), and BMI (± 15%). Panel B will consist of 8 subjects with moderate hepatic impairment and 8 healthy subjects matched for sex, age (± 5 yrs), and BMI (± 15%). Treatment in Panel A and Panel B will be conducted sequentially. Subjects in Panel A will receive a TMC278 25 mg tablet once daily for a total of 11 days. Recruitment for subjects for Panel B will start after evaluation of the safety, tolerability and pharmacokinetic data from subjects in Panel A. The anticipated dose of TMC278 to be administered to subjects in Panel B is the same dose as for Panel A (25 mg once daily for 11 days), but this dose might be adjusted depending on the results of Panel A.

Being tested
TMC278
Keywords
TMC278-TiDP6-C130, TMC278-C130, healthy volunteer, hepatic impairment, HIV Infections
Medical subject headings
Acquired Immunodeficiency Syndrome, HIV Infections

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TMC278Drug

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The primary objective of this study is to assess the single-dose and steady-state pharmacokinetics of TMC278 in subjects with mild or moderate hepatic impairment compared to matched healthy control subjects.

Secondary outcomes (1)

  1. The secondary objective of this study is to assess the short-term safety and tolerability of TMC278 in subjects with mild or moderate hepatic impairment compared to matched healthy control subjects.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Aug 2008 (estimated)
  2. Study startJun 2008
  3. Primary completionSep 2009
  4. Study completionNov 2009

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
32 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00736905
Sponsor's protocol ID
CR007465
Status last verified
Apr 2010
First submitted
14 Aug 2008
Last updated
28 Apr 2010
Results posted
No

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in